A Bayesian Cost-effectiveness analysis of Holobalance, Holograms for personalized virtual coaching and motivation in an ageing population with balance disorders
Abstract
Introduction: The world population is aging and it is only expected to grow in the next 30 years reaching 16% of the total world population (1). Globally, fall among older adults is a major public health problem.The burden of mortality and morbidity as a result of fall incidents is high in the elderly. There is a multitude of fall prevention programs designed based on the different risk factors associated with fall risk. Among these exercise programs have been shown to reduce the incidence of falls by 13% (6) to 40% (7).The Otago Exercise Program is an eight-week exercise that involves 17 different exercises that vary based on intensity with different repetitions and weight. It has been used as the cornerstone of most fall prevention exercise programs and has been shown to reduce fall risk in the elderly population by 35% (2,3). More recently, the use of virtual technologies has been an emerging phenomenon in the practice of elderly rehabilitation and exercise program. The Holobalance program, a novel methodology developed under the EU Horizon 2020 innovation project (8), was initiated to develop and validate a new personalized hologram coach platform for virtual coaching, motivation, and empowerment of the aging population with balance disorders. \nMethods: Bayesian cost-effectiveness analysis of two alternatives namely Otago Exercise Program and Holobalance technology is performed by considering the relevant probabilities of the outcomes, the associated cost, and utility…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.